A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

Novo Nordisk AS (NVO) reports a 25% sales increase, upgrades its full-year outlook, and addresses challenges in the insulin ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Three stocks that have been struggling of late but may be excellent long-term investments are Celsius Holdings (NASDAQ: CELH) ...

Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

American adults prefer dietary change as a weight loss method, over injectable weight loss drugs such as Ozempic, a survey says.

(THE CONVERSATION) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to ...

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people ...